AgingResearch.NewsJoin free

MSN

Company

MSN develops one asset, approved (riociguat in chronic thromboembolic pulmonary hypertension). Mostly small molecule acting on GUCY1A1 and GUCY1B1.

1
Asset
Furthest stage
Approved
0
Trials
1
Signal

Pipeline

1

  • riociguat

    Soluble guanylate cyclase stimulator enhancing cGMP production to cause vasodilation.

    Approved, Small molecule, GUCY1A1, GUCY1B1, chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies6

Intelligence